Caroline Bradford

NCHR Testimony to FDA on NeuroAD Therapy System in Alzheimer’s Patients

March 21, 2019. NCHR testifies at an FDA Neurological Devices Advisory Committee regarding NeuroAD, a proposed treatment for Alzheimer’s dementia.

FDA Slams Breast Implant Makers in Warning Letters Days Before Federal Hearing that Could Ban Them from the US Market

The Daily Mail: March 20, 2019. The FDA has finally issued warnings to two breast implant makers notifying them of incomplete safety studies that were mandatory for the implants to be on the market.

FDA Issues Warning to Two Breast Implant Makers

NBC News: March 19, 2019. The FDA released warning letters to two breast implant manufacturers in light of large numbers of women reporting complications.

Reports of Breast Implant Illnesses Prompt Federal Review

New York Times: March 19, 2019. With an overwhelmingly large number of women reporting adverse effects to their breast implants, collectively known as breast implant illness, the FDA finally agrees to review the devices.

What Does Gottlieb’s Resignation Mean for Medtech?

Medtech: March 6, 2019. FDA Commissioner Scott Gottlieb sent in his resignation, but what does it mean for drug and device safety? NCHR President, Dr. Zuckerman, weighs in.